Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 05 February, 2008

Summit Corporation PLC


Oxford, UK,  5 February  2008 -  Summit Corporation  plc (AIM:  SUMM)
today announces that two Non-executive Directors of the Company  have
taken all or part of their fees for the quarter ended 31 January 2008
in ordinary  shares pursuant  to  the Non-executive  Share  Ownership
Scheme that came into effect on 1 February 2007.

The purchase of Summit ordinary shares was made on 5 February 2008 at
a price of 90p  per share.   The number of  shares purchased and  the
total  holdings   following   these  purchases   of   the   Company's
Non-executive Directors are shown below:

| Non-executive  | Number of |  Total   |   Percentage of issued    |
|    Director    | ordinary  | holdings |      ordinary shares      |
|                |  shares   |          |                           |
|                | purchased |          |                           |
| Barry Price    |   4,534   |  14,615  |           0.03%           |
| (Non-executive |           |          |                           |
| Chairman)      |           |          |                           |
| George Elliott |   2,164   |  5,291   |           0.01%           |
|                |           |          |                           |

                              - ENDS -
For more information, please contact:

| Summit plc                             |                          |
| Steven  Lee,   PhD,  Chief   Executive | Tel: +44 (0)1235 443951  |
| Officer                                |                          |
| Darren   Millington,    ACMA,    Chief |                          |
| Financial Officer                      |                          |
| Richard Pye, PhD, Investor Relations   |                          |
|                                        |                          |
| Citigate Dewe Rogerson                 |                          |
| Mark Swallow / David Dible             | Tel: +44 (0)207 638 9571 |
|                                        |                          |
| Panmure Gordon                         |                          |
| Andrew Burnett / Rakesh Sharma         | Tel: +44 (0)207 459 3600 |

About Summit plc
Summit plc is a leading UK biotechnology company that discovers and
develops proprietary new drugs. The Company's internal drug
development programmes are underpinned by its advanced carbohydrate
chemistry and drug screening (chemical genomics) technology
platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the
clinical, pre-clinical and discovery stages of development, which
target serious diseases with a high unmet medical need. These
therapeutic areas include neuro-disorders (neurodegenerative and
neuromuscular), anti-infectives, ophthalmic diseases, oncology and
regenerative medicines.

Summit plc's in-house drug development capabilities combine
world-class expertise in both carbohydrate chemistry with
high-volume, high-content screening using its proprietary zebrafish
and fruitfly technologies (chemical genomics). These whole organism
screens have the potential to dramatically decrease the time and cost
of drug discovery and development by delivering data that are highly
predictive of the efficacy and toxicity of potential drug compounds
in humans.

The company listed on the AIM market of the London Stock Exchange in
October 2004 - symbol: SUMM

Further information about the company is available at

This document contains "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as
"anticipates", "intends", "plans", "seeks", "believes", "estimates",
"expects" and similar references to future periods, or by the
inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current
expectations and assumptions regarding our business, the economy and
other future conditions. Because forward-looking statements relate to
the future, by their nature, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult
to predict. The Company's actual results may differ materially from
those contemplated by the forward-looking statements. The Company
cautions you therefore that you should not rely on any of these
forward-looking statements as statements of historical fact or as
guarantees or assurances of future performance. Important factors
that could cause actual results to differ materially from those in
the forward-looking statements and regional, national, global
political, economic, business, competitive, market and regulatory